地特胰岛素联合α-糖苷酶抑制剂治疗2型糖尿病患者的临床研究

Clinical Study of Detemir in Combination with Alpha-glycosidase Inhibitor in the Treatment of Type 2 Diabetes

目的:分析2型糖尿病患者采用地特胰岛素联合α-糖苷酶抑制剂治疗的效果。方法:选取我院2018年2月至2018年11月收治的2型糖尿病患者194例,随机数字表法分为观察组(n=97)和对照组(n=97),对照组采用地特胰岛素治疗,观察组采用地特胰岛素联合α-糖苷酶抑制剂,均治疗2个月,比较治疗前后2组血糖[餐后2h血糖(2hPG)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)]水平、胰岛β功能指标[胰岛素抵抗指数(HOMA-IR)、空腹胰岛素(FINS)、胰岛β细胞功能指数(HOMA-β)]水平、血压(收缩压、舒张压)、体质量指数(BMI)及不良反应。结果:疗程结束后,2组2hPG、FPG、HbA1c水平较治疗前降低,且观察组较对照组降低明显(P<0.05);观察组HOMA-β、FINS较对照组高,HOMA-IR较对照组低(P<0.05);观察组舒张压、收缩压、BMI与对照组相比无显著变化(P>0.05);观察组不良反应发生率8.25%与对照组7.22%相比无显著差异(P>0.05)。结论:地特胰岛素联合α-糖苷酶抑制剂治疗2型糖尿病患者,可显著降低患者血糖水平,改善胰岛素功能,且不会对血压及体质量造成影响,不良反应少,安全性高。

Objective:To analyze therapeutic effect of detemir in combination with Alpha-glycosidase Inhibitor in patients with type 2 diabetes.Methods:From February 2018 to November 2018,194 patients with type 2 diabetes enrolled to our hospital were randomly divided into observation group(n=97)and control group(n=97).The control group was treated with detemir,while the observation group was treated with detemir combined with Alpha-glycosidase Inhibitor for 2 months.The blood glucose(2hPG),fasting blood glucose(FPG)and glycosylation of the two groups were compared before and after treatment.The levels of hemoglobin(HbA1c),insulin resistance index(HOMA-IR),fasting insulin(FINS),islet beta cell function index(HOMA-beta),blood pressure(systolic and diastolic blood pressure),body mass index(BMI)and adverse reactions were measured.Results:After the course of treatment,the levels of 2hPG,FPG and HbA1c in the two groups were lower than that before treatment,and the levels of HOMA-beta and FINS in the observation group were higher than that in the control group,and HOMA-IR in the observation group was lower than that in the control group(P<0.05).The diastolic blood pressure,systolic blood pressure and BMI in the observation group had no significant changes compared with that in the control group(P>0.05).The incidence of adverse reactions in the observation group was 8.25%compared with 7.22%in the control group,and there was no significant difference(P>0.05).Conclusion:Detemir in combination with Alpha-glycosidase Inhibitor in patients with type 2 diabetes can significantly reduce blood glucose levels and improve insulin function,without affecting blood pressure and body weight with fewer adverse reactions and higher safety.